Powerful NeOnc Brain Cancer Pipeline Advances

A September registered direct offering was priced at $4.20 per share and included accompanying warrants.

Rhea-AI Summary

NeOnc Technologies Holdings (NTHI) is scheduled to meet the FDA on November 17, 2026, about its investigational brain-cancer drug NEO212. The End-of-Phase 1 Type B meeting will cover proposed dosing, patient population, trial design and endpoints. NeOnc plans to ask whether a proposed Phase 2 design could potentially support an accelerated-approval pathway.

In Phase 1, NEO212 reached a protocol-defined maximum tolerated dose of 810 mg, and its recommended Phase 2 dose was set at 610 mg. One patient with recurrent glioblastoma had approximately 60% tumor reduction and 21 months of disease control; this individual observation is not proof of efficacy. Separately, NeOnc reported 48.9% six-month progression-free survival for NEO100 against a prespecified 20% benchmark in a Phase 2a study.

Positive

• None.

Negative

• September registered direct offering priced at $4.20 per share with warrants.

News Explained

NeOnc reports raising capital through a registered direct offering priced at $4.20 per share and accompanied by warrants; the release gives no share count, total proceeds or warrant terms. A registered direct is a negotiated sale of registered securities to selected investors.

Key Figures

FDA meeting date: November 17, 2026 Maximum tolerated dose: 810 mg Recommended Phase 2 dose: 610 mg +3 more

FDA meeting date

November 17, 2026

Scheduled End-of-Phase 1 Type B meeting for NEO212

Maximum tolerated dose

810 mg

NEO212 Phase 1 dose escalation

Recommended Phase 2 dose

610 mg

NEO212 dose established after Phase 1 escalation

Tumor reduction

Approximately 60%

Reported observation in one patient with recurrent glioblastoma

Disease control

21 months

Reported observation in one patient with recurrent glioblastoma

Stable disease duration

Approximately 16 months

Reported observation in one heavily pretreated patient with lung cancer metastatic to the brain

Key Terms

end-of-phase 1 type b meeting, accelerated-approval pathway, maximum tolerated dose, mgmt-methylated, +1 more

5 terms

end-of-phase 1 type b meeting regulatory

"in-person End-of-Phase 1 Type B meeting covering its experimental brain-cancer drug NEO212"

A U.S. Food and Drug Administration (FDA) "end-of-Phase 1" Type B meeting is a formal, scheduled discussion between a drug developer and regulators held after initial human safety testing (Phase 1). It focuses on the Phase 1 results, safety issues, and the design and data expectations for the next stage of development (Phase 2), serving like a checkpoint where the regulator and sponsor agree on what evidence is needed to move forward. This matters to investors because the meeting’s outcome can clarify timelines, required studies, and regulatory risk for a drug program.

accelerated-approval pathway regulatory

"could potentially support an accelerated-approval pathway"

A regulatory option that lets a drug or biologic reach the market sooner for serious or life-threatening conditions by relying on a surrogate or intermediate measure (like a lab result or tumor shrinkage) that is reasonably likely to predict real patient benefit, rather than waiting for longer-term outcomes. It matters to investors because it shortens time to sales and revenue but requires follow-up studies to confirm actual clinical benefit, similar to granting a provisional certificate based on early signs while a full exam continues.

maximum tolerated dose medical

"reached the protocol-defined maximum tolerated dose at 810 mg"

Maximum tolerated dose is the highest amount of a substance, such as a medication or chemical, that can be used without causing unacceptable side effects or harm. It’s like finding the maximum speed you can drive without risking a ticket or accident. For investors, understanding this concept helps gauge how much risk or exposure is safe or sustainable in a given situation.

mgmt-methylated medical

"recurrent IDH1 wild-type, MGMT-methylated glioblastoma"

MGMT-methylated indicates that the promoter region of the MGMT gene in tumor cells carries chemical methyl groups that reduce production of the MGMT DNA-repair enzyme. That reduced repair activity can make tumors more vulnerable to some DNA-damaging chemotherapies, so this biomarker is used in clinical trials and treatment decisions and can affect expected drug efficacy, trial outcomes, and commercial prospects for oncology therapies.

idh1 wild-type medical

"recurrent IDH1 wild-type, MGMT-methylated glioblastoma"

A tumor described as “IDH1 wild-type” has the normal, unmutated form of the IDH1 gene rather than a cancer-associated mutation. Like saying a recipe is unchanged, it signals that the cancer lacks that specific genetic alteration used to classify tumors, predict outcomes, or qualify patients for treatments that target IDH1 mutations. Investors track this because it affects how common certain therapies or diagnostic tests may be and who is eligible for them.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

November 17 FDA Meeting Set to Discuss Dosing and Trial Size for Second Drug in Pipeline

DENVER, Sept. 28, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) -- NeOnc Technologies Holdings (NASDAQ: NTHI) is putting another major date on the biotech calendar: November 17, 2026, when the company is scheduled to meet with the U.S. Food and Drug Administration for an in-person End-of-Phase 1 Type B meeting covering its experimental brain-cancer drug NEO212.

The meeting could become an important inflection point for a company that has rapidly assembled a string of clinical, regulatory and Wall Street catalysts.

NeOnc says it plans to seek FDA feedback on NEO212’s proposed patient population, trial design, endpoints, dose selection and the evidence that could ultimately support a marketing application. The company also intends to discuss a potential registrational strategy and whether a proposed Phase 2 design could potentially support an accelerated-approval pathway; marking a meaningful transition from dose-finding toward the next stage of clinical development.

NEO212 enters that meeting with some intriguing, though still preliminary, human data.

During Phase 1, dose escalation reached the protocol-defined maximum tolerated dose at 810 mg, after which the recommended Phase 2 dose was established at 610 mg. The company has highlighted a patient with recurrent IDH1 wild-type, MGMT-methylated glioblastoma who experienced an approximately 60% tumor reduction and 21 months of disease control. Another heavily pretreated patient with lung cancer metastatic to the brain experienced stable disease for approximately 16 months. These are individual patient observations, not proof of efficacy, and larger trials will have to determine whether the results can be replicated.

NeOnc CEO Amir Heshmatpour put the immediate objective plainly: “This meeting will help us understand FDA’s feedback on the population, study design and endpoints for the next stage of development.”

The NEO212 catalyst arrives as the broader NeOnc story is also attracting Wall Street attention. Roth Capital recently initiated coverage of NeOnc with a $20 price target, with analyst Jonathan Aschoff reportedly anticipating potential pivotal-trial starts by the end of 2026.

NeOnc is now advancing two potential therapies in its CNS cancer pipeline, giving investors more than one clinical catalyst to watch. Its lead program, NEO100, recently generated topline Phase 2a data in recurrent IDH1-mutant high-grade glioma, with the company reporting six-month progression-free survival of 48.9% versus a prespecified 20% benchmark and median overall survival of 26.09 months. NeOnc said it plans to engage with the FDA regarding a potential registrational pathway.

The parallel development tracks could give NeOnc multiple potential catalysts heading into 2027. Roth Capital’s research indicates Aschoff expects an FDA Type B End-of-Phase 2 meeting for NEO100 in October and sees potential pivotal-trial starts before the end of 2026.

Meanwhile, NeOnc has raised capital from institutional investors, including a September registered direct offering priced at $4.20 per share and accompanying warrants. Company insiders have also been active buyers: SEC filings show recent open-market purchases by executives including Heshmatpour and Thomas C. Chen.

That backdrop makes November 17 particularly interesting. NTHI is approaching the FDA with a defined Phase 2 dose, early signals of clinical activity and a stated ambition to develop NEO212 across difficult-to-treat CNS cancers.

If the agency provides a workable path forward on population, endpoints and study design, NEO212 could emerge from the meeting with a substantially clearer development roadmap.

For NTHI shareholders, November 17 is therefore less about expecting an approval and more about watching whether the FDA conversation turns NEO212 from an intriguing clinical program into a more clearly defined late-stage development story.

About 24/7 Market News

In today's fast-moving markets, visibility is everything and 24/7 Market News (24/7) provides a powerful suite of investor relations and public relations solutions designed to elevate your company’s profile quickly and effectively. Whether you're an established name seeking broader awareness, or a micro-cap looking to break out of obscurity, 24/7 delivers targeted, high-impact coverage through timely news distribution, analyst report placements, featured editorials, and multi-channel amplification across financial platforms, social media, and investor communities. Our services help cut through the noise, attract institutional interest, drive exposure, and build long-term shareholder credibility, all while maintaining full SEC compliance and transparency. For Analyst Report coverage, custom IR campaigns, press release syndication, or other tailored investor and public relations solutions, contact sales@247mnn.com to discuss how 24/7 can help accelerate your company’s visibility and valuation trajectory.

PAID EDITORIAL DISCLOSURE: This is a paid editorial communication intended for informational purposes only. 24/7 is compensated by NTHI to provide ongoing news coverage of expected upcoming catalysts and events as well as market outreach services. For further disclosure information, please click here. This should not be construed as financial or investment advice. Trading involves substantial risk; consult your financial advisor.

Important Editorial Note: 247 highlights companies approaching significant catalysts and inflection points. This report reflects information available at the time of publication. Since developments can occur rapidly, readers should independently verify current information and review all company filings and disclosures.

CONTACT:
24/7 Market News
Editor@247mnn.com

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding the Company's ability to grow its business and other statements that are not historical facts, including statements which may be accompanied by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Actual results could differ materially from those described in these forward-looking statements due to a number of factors, including without limitation, the Company's ability to continue as a going concern, general economic conditions, and other risk factors detailed in the Company's filings with the SEC. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake any responsibility to update such forward-looking statements except in accordance with applicable law.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When is NeOnc's FDA meeting for NEO212, and what will it cover?

NeOnc is scheduled to meet the FDA in person on November 17, 2026, for an End-of-Phase 1 Type B discussion about NEO212. The company plans to seek feedback on the proposed patient population, trial design, endpoints, dose selection and evidence that could support a marketing application.

What other patient observation did NeOnc report for NEO212?

A heavily pretreated patient with lung cancer metastatic to the brain had stable disease for approximately 16 months. This is an individual patient observation, not proof that NEO212 is effective.